Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Spotlight picks
- Trial result Spotlight
Breast cancer
RLY-2608 Mutant-Selective PI3Kα Inhibitor Achieves 31% ORR and 9-Month mPFS with Minimal Grade 3 Hyperglycemia in Post-CDK4/6 HR+/HER2⁻ mBC
RLY-2608 is an oral, allosteric PI3Kα inhibitor that binds only oncogenic PIK3CA variants, sparing wild-type signaling to reduce metabolic toxicity. In the phase 1 ReDiscover trial, 52 heavily pre-treated HR+/HER2⁻…
- Trial result Spotlight
Breast cancer
T-DXd + Pyrotinib Hits 100% PR in Phase Ib First-Line HER2-Positive mBC (TROPHY)
Trastuzumab deruxtecan (T-DXd), a HER2-directed topoisomerase-I ADC, was paired with the irreversible pan-HER TKI pyrotinib in the TROPHY phase Ib dose-finding study (NCT06245824). Five previously untreated…
NCT06245824 - Trial result Spotlight
Breast cancer
Rezatapopt Restores Mutant p53, Yields 38% ORR in Heavily Pretreated TP53 Y220C-Mutated Metastatic Breast Cancer
Rezatapopt (PC14586) is an oral, first-in-class small-molecule that binds the p53 Y220C pocket, refolding the mutant protein into a wild-type conformation and reactivating tumor-suppressor function. In the Phase 1…
NCT04585750 - Trial result Spotlight
Breast cancer
Chemo-Free Durvalumab + Trastuzumab + Pertuzumab Yields 49% pCR (68% RCB0/1) in HER2-Enriched Early Breast Cancer
The single-arm Phase II DTP trial (NCT03820141) treated 39 stage I–III, ER/PR-negative, (by a BluePrint [BP] 80-gene molecular subtyping test that classifies early-stage breast cancer (EBC) into Basal, Luminal, and…
NCT03820141 - Trial result Spotlight
Non-small cell lung cancer
Perioperative PD-1 Blockade (Nivolumab) + Chemo Pushes 30-mo EFS to 61% in Resectable NSCLC
Nivolumab, an anti-PD-1 antibody, given with four neoadjuvant platinum-doublet cycles and up to a year of adjuvant monotherapy (CheckMate 77T, n = 461 stage IIA–IIIB) achieved median event-free survival of 46.6 mo vs…
- Trial result Spotlight
Other blood cancers and transplant
Revumenib + AZA/VEN Hits 88% ORR and Universal MRD-Negativity in Older NPM1m/KMT2Ar AML
Revumenib, an oral menin inhibitor that disrupts the menin-KMT2A/NPM1 transcriptional axis, was added to frontline azacitidine + venetoclax in a phase I dose-escalation/expansion study (NCT03013998) enrolling 43…
NCT03013998 - Trial result Spotlight
Head and neck cancer
Ulevostinag (STING agonist) + Pembrolizumab Scores 50% ORR in First-Line R/M HNSCC
Ulevostinag, a cyclic-dinucleotide STING agonist given intratumorally at its RP2D 540 µg, was tested with pembrolizumab 200 mg Q3W in a phase 1 dose-escalation (n = 156) and a small randomized phase 2 head-to-head in…
- Trial result Spotlight
Breast cancer
T-DXd HER2 ADC nearly doubles PFS over chemo in HER2-low HR+ mBC
Trastuzumab deruxtecan (T-DXd), an anti-HER2/topo-I antibody-drug conjugate, was pitted against capecitabine or taxane chemotherapy in the phase 3 DESTINY-Breast06 trial (NCT04494425). In the 625-patients with ctDNA…
NCT04494425 - Trial result Spotlight
Breast cancer
Camizestrant Switch Halves Progression Risk in Emerging ESR1-Mutant HR+/HER2- mBC
Camizestrant, a next-generation oral selective estrogen-receptor degrader, was tested in the phase 3 SERENA-6 trial (NCT04964934). 315 ER-positive/HER2-negative metastatic breast cancer patients who developed an ESR1…
NCT04964934 - Trial result Spotlight
Head and neck cancer
HPV16-Targeted Vaccine PDS0101 + Pembrolizumab Pushes 1L OS to 30–39 mo in Recurrent/Metastatic HNSCC
PDS0101 (Versamune® HPV16) is a synthetic lipid nanoparticle vaccine that primes HPV16-specific CD4 and CD8 T cells. In the single-arm Phase 2 VERSATILE-002 trial (NCT04260126), it was combined with pembrolizumab…
NCT04260126 - Trial result Spotlight
Lymphoma
Epcoritamab (CD20×CD3 bispecific, subcutaneous) tops chemoimmunotherapy and other bispecifics (mosunetuzumab and odronextamab) in ≥2-line relapsed follicular lymphoma
In a matching-adjusted indirect comparison of the EPCORE-NHL-1 FL cohort (≈127 pts) against real-world standard of care/chemoimmunotherapy (SOC/CIT) from SCHOLAR-5 and trial arms of two CD20xCD3 bispecific antibodies…
- Trial result Spotlight
Uterine (endometrial) cancer
Rinatabart Sesutecan FRα-ADC Yields ~50% ORR After PD-1/Platinum Failure in Advanced Endometrial Cancer
Rinatabart sesutecan is a folate-receptor-α–targeted antibody-drug conjugate linked to the exatecan topoisomerase-I payload. In the GTC1184-01 phase 1/2 expansion (NCT05579366), 64 heavily pre-treated metastatic…
NCT05579366 - Trial result Spotlight
Multiple solid tumors
Mismatch-Repair Gene Shapes Immune Checkpoint Blocker Outcomes: MLH1/MSH2 Hit 40-46% CR, PMS2 Falls to 9% and 20-mo OS
In a retrospective MSK-IMPACT series (NCT01775072), 132 patients with Lynch syndrome and advanced solid tumors—including colorectal cancer (35%), genitourinary cancers (14%), and pancreatic or biliary cancers…
NCT01775072 - Trial result Spotlight
Melanoma
ROR2-targeted ADC ozuriftamab achieves 80% response and 5-year CR in refractory melanoma
Ozuriftamab vedotin is a conditionally active anti-ROR2 antibody–drug conjugate that releases MMAE within the acidic tumor microenvironment. ROR2 is expected to be important to signaling in melanoma and is expressed…
NCT03504488
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.